Please login to the form below

Not currently logged in
Email:
Password:

quarterly sales

This page shows the latest quarterly sales news and features for those working in and with pharma, biotech and healthcare.

Novartis stumbles in Q2 as COVID-19 impacts sales

Novartis stumbles in Q2 as COVID-19 impacts sales

Net profit drops by 4% as pandemic hits sales. Swiss pharma company Novartis has reported a drop in its quarterly sales and profit as the COVID-19 pandemic impacts its 2020 ... Net sales in the quarter from continuing operations declined by 1% to $11.3bn

Latest news

  • Biogen files Tecfidera follow-up in the US Biogen files Tecfidera follow-up in the US

    The tolerability issue hasn’t held back Tecfidera commercially, however, with quarterly sales currently running at more than $1bn, despite tougher competition overall in the MS market.

  • Generic threat looms to J&J’s blockbuster Zytiga in US Generic threat looms to J&J’s blockbuster Zytiga in US

    launches. The importance of Zytiga to J&J at the moment can’t really be overstated: its  quarterly sales are nearly $1bn – well over half from the US – and growing at ... Zytiga will enter the market and will result in a significant decline in

  • AZ agrees to $320m deal for Zoladex AZ agrees to $320m deal for Zoladex

    products. The deal, which is expected to close by the end of March, will see AZ receive a $250m upfront payment for the rights, with double-digit quarterly sales-based payments ... ongoing. A further $70m is also up for grabs should Zoladex (goserelin

  • GSK's Witty ends on a high, but warns 2017 looking 'uncertain' GSK's Witty ends on a high, but warns 2017 looking 'uncertain'

    Generic competition to big-selling Seretide/Advair in the US could accelerate sales decline. ... Other generics from Mylan and Hikma are under regulatory review, however, which could be directly substitutable and accelerate the decline in the brand's

  • 2017 set to be a 2017 set to be a "defining year" for AZ

    The last AZ drug to fall over the 'patent cliff' - cholesterol-lowerer Crestor (rosuvastatin) - saw sales cut in half in the fourth quarter after the loss of US patent protection, with ... The decline was, however, offset by good growth for non-small

More from news
Approximately 9 fully matching, plus 28 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health®

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics